The global blood transfusion diagnostics market size was valued at around USD 4.8 billion in 2021 and is projected to grow at a compound annual rate of growth (CAGR) of around 7.2% from 2022 to 2032.The market size is projected to succeed in USD 9.3 billion by 2032.

Based on product type, the market can be segmented into instruments, reagents and kits, and software and services. The reagents and kits segment dominated the market in 2020, accounting for a share of 48.8%. The high demand for blood screening and testing reagents and kits, coupled with the increasing prevalence of blood disorders, is driving the growth of this segment. The instruments segment is also expected to grow significantly in the coming years, driven by technological advancements in blood screening and testing equipment.

Based on technology, the market can be segmented into nucleic acid testing, enzyme-linked immunosorbent assay (ELISA), rapid tests, and western blotting. The nucleic acid testing segment dominated the market in 2020, accounting for a share of 40.5%. The high sensitivity and specificity of nucleic acid testing methods for detecting blood-borne infections, such as HIV and hepatitis, are driving the growth of this segment. The ELISA segment is also expected to grow significantly in the coming years, driven by its wide application in blood screening and testing.

Based on end-user, the market can be segmented into hospitals, blood banks, diagnostic laboratories, and others. The hospitals segment dominated the market in 2020, accounting for a share of 39.8%. The high demand for blood transfusions in hospitals, coupled with the increasing adoption of blood screening and testing methods, is driving the growth of this segment. The blood banks segment is also expected to grow significantly in the coming years, driven by the increasing demand for safe blood transfusions.

Geographically, the market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the market in 2020, accounting for a share of 34.8%. The high prevalence of blood disorders, coupled with the increasing adoption of blood screening and testing methods, is driving the growth of the market in this region. Asia Pacific is also expected to grow significantly in the coming years, driven by the rising demand for blood transfusions and increasing healthcare expenditure in the region.

Some of the key players operating in the global blood transfusion diagnostics market include Bio-Rad Laboratories, Inc., Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, Grifols, S.A., F. Hoffmann-La Roche Ltd., Ortho Clinical Diagnostics, Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Immucor, Inc.

In conclusion, the global blood transfusion diagnostics market is expected to grow significantly in the coming years, driven by the rising prevalence of blood disorders, increasing demand for safe blood transfusions, and technological advancements in blood screening and testing. The reagents and kits segment dominated the market in 2020, while the nucleic acid testing segment dominated the market based on technology. North America dominated the market geographically, while Asia Pacific is expected to grow significantly in the coming years.